The current stock price of PAND is 60.05 null. In the past month the price decreased by -2.56%.
ChartMill assigns a technical rating of 6 / 10 to PAND.
ChartMill assigns a fundamental rating of 1 / 10 to PAND. PAND has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months PAND reported a non-GAAP Earnings per Share(EPS) of -2.8116. The EPS increased by 86.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -434.05% | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
Pandion Therapeutics Inc. is a biotechnology company. It focuses on developing modular proteins, antibodies and bispecifics for the treatment of autoimmune and inflammatory diseases. Pandion Therapeutics Inc. is based in North Cambridge, United States.
Pandion Therapeutics Inc
134 COOLIDGE AVENUE 2ND FLOOR
WATERTOWN MA 02472
CEO: Rahul Kakkar
Phone: 617-393-5925
Pandion Therapeutics Inc. is a biotechnology company. It focuses on developing modular proteins, antibodies and bispecifics for the treatment of autoimmune and inflammatory diseases. Pandion Therapeutics Inc. is based in North Cambridge, United States.
The current stock price of PAND is 60.05 null. The price increased by 0.22% in the last trading session.
PAND does not pay a dividend.
PAND has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Pandion Therapeutics Inc (PAND) has a market capitalization of 1.77B null. This makes PAND a Small Cap stock.